Lisa Aschenbrenner

机构：Pfizer (United States), PRX Research · ORCID：0009-0005-2921-068X

发表论文 19 篇 · 总被引 3072 次 · h-index 16

代表论文

• An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 (2021 · Science · 被引 1969)
• Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 (2021 · Nature Communications · 被引 297)
• Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19 (2020 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 159)
• Acoustic Ejection Mass Spectrometry for High-Throughput Analysis (2021 · Analytical Chemistry · 被引 111)
• Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam (2012 · Antimicrobial Agents and Chemotherapy · 被引 89)
• A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 (2024 · Journal of Medicinal Chemistry · 被引 81)